Review Article

A Network Meta-Analysis on Randomized Trials Focusing on the Preventive Effect of Statins on Contrast-Induced Nephropathy

Table 4

Effect estimates for the risk of contrast-induced nephropathy. Results are reported as probability of being treatment (Pbest) and odds ratios (OR) with 95% credible intervals of a given row item versus a corresponding column item. Thus, OR < 1 indicates lower risk in the corresponding row item and OR > 1 indicates lower risk in the corresponding column item.

TreatmentAtorvastatin high doseAtorvastatin low doseRosuvastatin high doseSimvastatin high doseSimvastatin low dosePlacebo or no statin

Atorvastatin high dose Pbest = 34%OR = 0.33 (0.16–0.63)OR = 1.00 (0.61–1.64)OR = 0.69 (0.12–4.35)OR = 0.22 (0.03–1.35)OR = 0.49 (0.32–0.74)
Atorvastatin low doseOR = 3.05 (1.59–6.21) Pbest < 0.1%OR = 3.85 (1.27–14.29)OR = 2.86 (0.41–24.39)OR = 0.67 (0.09–5.01)OR = 1.49 (0.69–3.45)
Rosuvastatin high doseOR = 1.00 (0.61–1.63)OR = 0.26 (0.07–0.79) Pbest = 34%OR = 0.76 (0.14–4.55)OR = 0.73 (0.16–3.70)OR = 0.49 (0.34–0.69)
Simvastatin high doseOR = 1.44 (0.23–8.11)OR = 0.35 (0.04–2.42)OR = 1.32 (0.22–7.13) Pbest = 32%OR = 0.29 (0.10–0.72)OR = 0.66 (0.14–3.04)
Simvastatin low doseOR = 4.61 (0.74–30.37)OR = 1.50 (0.20–10.86)OR = 1.37 (0.27–6.42)OR = 3.40 (1.38–9.88) Pbest = 0.2%OR = 2.25 (0.37–14.61)
Placebo or
no statin
OR = 2.05 (1.35–3.09)OR = 0.67 (0.29–1.44)OR = 2.04 (1.44–2.94) OR = 1.51 (0.33–7.14)OR = 0.44 (0.07–2.70) Pbest = 0